SG11201801110TA - Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient - Google Patents

Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient

Info

Publication number: SG11201801110TA
Authority: SG; Singapore
Prior art keywords: naphthyridine; carboxamide; methoxyphenyl; dihydro; ethoxy
Prior art date: 2015-08-21

Application number

SG11201801110TA

Inventor

Johannes Platzek

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-21

Filing date

2016-08-18

Publication date

2018-03-28

2016-08-18 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2018-03-28 Publication of SG11201801110TA publication Critical patent/SG11201801110TA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Psychology (AREA)
Pulmonology (AREA)

SG11201801110TA 2015-08-21 2016-08-18 Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient SG11201801110TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP15182043		2015-08-21
PCT/EP2016/069558 WO2017032673A1 (en)	2015-08-21	2016-08-18	Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient

Publications (1)

Publication Number	Publication Date
SG11201801110TA true SG11201801110TA (en)	2018-03-28

Family

ID=53938271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201801110TA SG11201801110TA (en)	2015-08-21	2016-08-18	Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient

Country Status (31)

Country	Link
US (2)	US10336749B2 (en)
EP (1)	EP3337800B1 (en)
JP (1)	JP6824247B2 (en)
KR (1)	KR102669559B1 (en)
CN (1)	CN107849043B (en)
AR (1)	AR105774A1 (en)
AU (1)	AU2016312904C1 (en)
CA (1)	CA2995905A1 (en)
CL (1)	CL2018000427A1 (en)
CO (1)	CO2018001466A2 (en)
DK (1)	DK3337800T3 (en)
ES (1)	ES2739904T3 (en)
HK (1)	HK1251565A1 (en)
HR (1)	HRP20191431T1 (en)
HU (1)	HUE044574T2 (en)
IL (1)	IL257371B (en)
JO (1)	JOP20160186B1 (en)
LT (1)	LT3337800T (en)
MX (1)	MX367960B (en)
MY (1)	MY195226A (en)
PE (1)	PE20180554A1 (en)
PL (1)	PL3337800T3 (en)
PT (1)	PT3337800T (en)
RS (1)	RS59055B1 (en)
RU (1)	RU2743429C2 (en)
SG (1)	SG11201801110TA (en)
SI (1)	SI3337800T1 (en)
TW (1)	TWI725045B (en)
UY (1)	UY36864A (en)
WO (1)	WO2017032673A1 (en)
ZA (1)	ZA201801859B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110317265B (en) *	2018-03-28	2023-03-10	江苏豪森药业集团有限公司	Bivalirudin crystal form A and preparation method thereof
EP3560922A1 (en) *	2018-04-24	2019-10-30	Bayer Aktiengesellschaft	Process for preparation of (4s) - 4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide by racemate resoution through diastereomeric tartaric acid
EP3566704A1 (en)	2018-05-11	2019-11-13	Bayer Aktiengesellschaft	The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases
CR20220161A (en) *	2019-10-17	2022-06-17	Bayer Ag	Process for producing acyloxymethyl esters of (4s)-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylic acid
CN115340539B (en)	2022-01-19	2024-02-27	奥锐特药业股份有限公司	Process for preparing non-nereirenone and intermediates thereof
CN114524812A (en) *	2022-03-18	2022-05-24	湖南凯铂生物药业有限公司	Crystal form preparation and synthesis method of 1, 4-dihydro-1, 6-naphthyridine compound
WO2023205164A1 (en)	2022-04-18	2023-10-26	Teva Pharmaceuticals International Gmbh	Processes for the preparation of finerenone
WO2024075139A1 (en) *	2022-10-06	2024-04-11	Maithri Drugs Private Limited	A process for preparation of finerenone and intermediates thereof
WO2024193455A1 (en) *	2023-03-17	2024-09-26	江苏恒瑞医药股份有限公司	Pharmaceutically acceptable salt and crystal form of 1,4-dihydro-1,6-naphthyridine amide compound and preparation method therefor
CN116715664A (en) *	2023-06-12	2023-09-08	常州制药厂有限公司	Preparation method of non-neridrone key intermediate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3431303A1 (en) *	1984-08-25	1986-02-27	Goedecke Ag	1,6-Naphthyridine derivatives, process for their preparation and their use
IL75987A (en) *	1984-08-25	1991-07-18	Goedecke Ag	Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
EP1043314A4 (en) *	1997-12-22	2001-01-24	Ajinomoto Kk	Novel dihydropyridine derivative
DE19834044A1 (en)	1998-07-29	2000-02-03	Bayer Ag	New substituted pyrazole derivatives
DE19834047A1 (en)	1998-07-29	2000-02-03	Bayer Ag	Substituted pyrazole derivatives
DE19943636A1 (en)	1999-09-13	2001-03-15	Bayer Ag	Novel dicarboxylic acid derivatives with pharmaceutical properties
DE19943635A1 (en)	1999-09-13	2001-03-15	Bayer Ag	Novel aminodicarboxylic acid derivatives with pharmaceutical properties
DE19943639A1 (en)	1999-09-13	2001-03-15	Bayer Ag	Dicarboxylic acid derivatives with novel pharmaceutical properties
DE19943634A1 (en)	1999-09-13	2001-04-12	Bayer Ag	Novel dicarboxylic acid derivatives with pharmaceutical properties
AR031176A1 (en)	2000-11-22	2003-09-10	Bayer Ag	NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
DE10110750A1 (en)	2001-03-07	2002-09-12	Bayer Ag	Novel aminodicarboxylic acid derivatives with pharmaceutical properties
DE10110749A1 (en)	2001-03-07	2002-09-12	Bayer Ag	Substituted aminodicarboxylic acid derivatives
DE10220570A1 (en)	2002-05-08	2003-11-20	Bayer Ag	Carbamate-substituted pyrazolopyridines
US20080312209A1 (en)	2005-07-12	2008-12-18	Glaxo Group Limited	Piperazine Heteroaryl Derivatives as Gpr38 Agonists
DE102006026583A1 (en) *	2006-06-07	2007-12-13	Bayer Healthcare Aktiengesellschaft	Aryl-substituted hetero-bicyclic compounds and their use
DE102007009494A1 (en) *	2007-02-27	2008-08-28	Bayer Healthcare Ag	New 1,6-naphthyridine or 8-azaquinazoline derivatives useful for treating aldosteronism, hypertension, cardiac insufficiency, myocardial infarct sequelae, liver cirrhosis, renal insufficiency and stroke
MX369467B (en) *	2014-08-01	2019-11-08	Bayer Pharma AG	Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5- ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient.

2016
- 2016-08-18 PT PT16753388T patent/PT3337800T/en unknown
- 2016-08-18 SG SG11201801110TA patent/SG11201801110TA/en unknown
- 2016-08-18 RS RS20190985A patent/RS59055B1/en unknown
- 2016-08-18 JP JP2018509768A patent/JP6824247B2/en active Active
- 2016-08-18 PE PE2018000259A patent/PE20180554A1/en unknown
- 2016-08-18 HU HUE16753388 patent/HUE044574T2/en unknown
- 2016-08-18 US US15/753,849 patent/US10336749B2/en not_active Ceased
- 2016-08-18 MY MYPI2018700615A patent/MY195226A/en unknown
- 2016-08-18 EP EP16753388.4A patent/EP3337800B1/en active Active
- 2016-08-18 TW TW105126338A patent/TWI725045B/en active
- 2016-08-18 CA CA2995905A patent/CA2995905A1/en active Pending
- 2016-08-18 LT LTEP16753388.4T patent/LT3337800T/en unknown
- 2016-08-18 WO PCT/EP2016/069558 patent/WO2017032673A1/en active Application Filing
- 2016-08-18 DK DK16753388.4T patent/DK3337800T3/en active
- 2016-08-18 CN CN201680047659.XA patent/CN107849043B/en active Active
- 2016-08-18 RU RU2018109761A patent/RU2743429C2/en active
- 2016-08-18 ES ES16753388T patent/ES2739904T3/en active Active
- 2016-08-18 JO JOP/2016/0186A patent/JOP20160186B1/en active
- 2016-08-18 US US17/367,066 patent/USRE49826E1/en active Active
- 2016-08-18 SI SI201630305T patent/SI3337800T1/en unknown
- 2016-08-18 KR KR1020187004893A patent/KR102669559B1/en active IP Right Grant
- 2016-08-18 AU AU2016312904A patent/AU2016312904C1/en active Active
- 2016-08-18 MX MX2018002027A patent/MX367960B/en active IP Right Grant
- 2016-08-18 PL PL16753388T patent/PL3337800T3/en unknown
- 2016-08-19 UY UY0001036864A patent/UY36864A/en active IP Right Grant
- 2016-08-19 AR ARP160102552A patent/AR105774A1/en unknown
2018
- 2018-02-06 IL IL257371A patent/IL257371B/en active IP Right Grant
- 2018-02-14 CO CONC2018/0001466A patent/CO2018001466A2/en unknown
- 2018-02-16 CL CL2018000427A patent/CL2018000427A1/en unknown
- 2018-03-20 ZA ZA201801859A patent/ZA201801859B/en unknown
- 2018-08-28 HK HK18111022.9A patent/HK1251565A1/en unknown
2019
- 2019-08-07 HR HRP20191431 patent/HRP20191431T1/en unknown

Also Published As

Publication number	Publication date
UY36864A (en)	2017-03-31
SI3337800T1 (en)	2019-08-30
RU2743429C2 (en)	2021-02-18
DK3337800T3 (en)	2019-08-19
AU2016312904B2 (en)	2020-12-10
RS59055B1 (en)	2019-08-30
HK1251565A1 (en)	2019-02-01
PT3337800T (en)	2019-08-05
IL257371B (en)	2021-04-29
ZA201801859B (en)	2019-11-27
MX2018002027A (en)	2018-06-15
CN107849043A (en)	2018-03-27
US20180244670A1 (en)	2018-08-30
US10336749B2 (en)	2019-07-02
HRP20191431T1 (en)	2019-11-01
AU2016312904C1 (en)	2021-05-27
AU2016312904A1 (en)	2018-03-08
CN107849043B (en)	2020-10-16
LT3337800T (en)	2019-08-12
WO2017032673A1 (en)	2017-03-02
AR105774A1 (en)	2017-11-08
CO2018001466A2 (en)	2018-02-28
MY195226A (en)	2023-01-11
USRE49826E1 (en)	2024-02-06
IL257371A (en)	2018-04-30
CA2995905A1 (en)	2017-03-02
JOP20160186B1 (en)	2021-08-17
MX367960B (en)	2019-09-12
RU2018109761A3 (en)	2020-01-21
EP3337800A1 (en)	2018-06-27
EP3337800B1 (en)	2019-06-12
RU2018109761A (en)	2019-09-23
KR102669559B1 (en)	2024-05-28
HUE044574T2 (en)	2019-11-28
JP2018523699A (en)	2018-08-23
TW201722944A (en)	2017-07-01
TWI725045B (en)	2021-04-21
JP6824247B2 (en)	2021-02-03
AU2016312904B9 (en)	2020-12-24
PE20180554A1 (en)	2018-04-02
PL3337800T3 (en)	2019-10-31
ES2739904T3 (en)	2020-02-04
KR20180041138A (en)	2018-04-23
CL2018000427A1 (en)	2018-07-20

Publication	Publication Date	Title
IL250239B (en)	2019-09-26	Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
HK1251565A1 (en)	2019-02-01	Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
IL256085B (en)	2021-02-28	A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
IL252477B (en)	2021-04-29	2-[(3-ethenyl-carbonyl-amino)anilino]-pyrimidine derivatives, process for their preparation and pharmaceutical compositions comprising them
EP3284738A4 (en)	2018-09-12	5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
SG11201605868XA (en)	2016-08-30	Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
ZA201805600B (en)	2023-02-22	Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
HK1217303A1 (en)	2017-01-06	Pharmaceutical composition for treatment of leukemia and preparation method thereof
SG11201610636VA (en)	2017-01-27	Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
HK1191654A1 (en)	2014-08-01	Sterol derivatives, method for preparing same, pharmaceutical compositions containing same and use thereof for the treatment of multiple glioblastomas
EP3284743A4 (en)	2018-04-25	Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
ZA201801865B (en)	2019-11-27	Method for the preparation of the metabolites of (4s)- and (4r)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and the use thereof
HK1245094A1 (en)	2018-08-24	Pharmaceutical composition for treatment of depression and preparation method thereof
IL280389A (en)	2021-03-01	A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
HUP1500356A2 (en)	2017-03-28	Nanocomposite, suitable for the controlled release of active ingredients of the central nervous system, the preparation method and use thereof
ZA201504702B (en)	2016-05-25	Solid pharmaceutical composition containing low dose entecavir and method of preparation thereof
GB201511863D0 (en)	2015-08-19	Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same